Cost-effective risk assessment of nanomaterials may be feasible Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.
New Lyme disease study in the Netherlands At the start of the “Tick Awareness Week”, the Dutch National Institute for Public Health and the Environment (RIVM) and Wageningen UR are commencing a large-scale study on the long-term effects of
Innovation required in risk assessment of nanoparticles The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.
RIVM designated as WHO Collaborating Centre Antimicrobial Resistance Epidemiology and Surveillance AMR is one of the major global challenges in infectious disease control.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.
European Antibiotic Awareness Day 2014 Tuesday 18 November is European Antibiotic Awareness Day. On this day, throughout Europe, attention is focused on the responsible use of antibiotics for people and animals.
Antibiotic resistance no longer increasing but vigilance remains necessary After continuing to rise for many years, in 2013 the prevalence of resistance to antibiotics levelled out somewhat in both hospitals and primary care.
International top conference about antibiotic resistance On 25 and 26 June, an international conference about resistance to antibiotics - an increasing worldwide problem - will take place in The Hague.
RIVM film about nanomaterials RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.